Tuesday, November 17, 2026

Fujitsu, together with pharmaceutical companies and medical institutions, creates an ecosystem to accelerate the digitalization of clinical trials! Eliminating Drug Losses in Japan

Under the "Fujitsu Uvance" business model, which aims to solve social issues through cross-industry collaboration, Fujitsu is working to improve people's wellbeing through "Healthy Living", and has launched an initiative to attract international joint clinical trials to Japan by building a new ecosystem that utilizes medical data in the clinical trial area with pharmaceutical companies and medical institutions to solve drug loss issues where new drugs approved overseas are not available in Japan. In order to solve the problem of drug loss in Japan, we will start an initiative to attract international clinical trials to Japan by building a new ecosystem that utilizes medical data in the clinical trial area, together with pharmaceutical companies, medical institutions, etc!

Toward a society where patients have early access to the medicines they need and can choose the treatment that is right for them

Fujitsu Limited signed a strategic partnership agreement with Paradigm Health, Inc. (Paradigm), Fujitsu's Healthy Living Platform, a platform for utilizing medical data, and Fujitsu Kozuchi, an AI service, will facilitate the collection and processing of medical data held by medical institutions, thereby increasing the efficiency of clinical trial planning operations and shortening the time required for clinical trials.

In addition, as a new offering of Healthy Living, Patient-centric Clinical Trials, Fujitsu's LLM-based automated clinical trial document creation service will be available from August 26, 2024.

In the future, Fujitsu will expand the scope of its support not only to clinical trial planning but also to the subsequent execution phase, thereby resolving issues related to the entire clinical trial process. In this way, Fujitsu aims to achieve sales of 20 billion yen in the clinical trial area in fiscal 2030 and contribute to the realization of a society in which patients can obtain necessary drugs at an early stage and can choose the treatment that is right for them.

background

In Japan, patients for clinical trials are dispersed among multiple hospitals, which requires a large amount of time and money to collect the cases needed for clinical trial planning. Combined with measures to suppress drug prices, Japan is increasingly being excluded from regions targeted by global clinical trials designed to develop new drugs on a global scale.

As a result, as of March 2023, there are 143 drugs (Note 2) that are in practical use overseas but unapproved in Japan, and the problem of drug loss, where drugs approved overseas cannot be administered in Japan, is becoming more serious.

Outline of Initiatives

1. accelerate digitalization of clinical trials through partnership with Paradigm
Fujitsu has partnered with Paradigm, a U.S. company that provides one-stop support for pharmaceutical companies and medical institutions in the process of clinical trials from planning to execution, to create a new clinical trial environment that utilizes medical data, which has been difficult to achieve in the past. The partnership will combine Paradigm's clinical trial platform, which boasts an overwhelming number of global clinical trials with Fujitsu's business support know-how, services and cutting-edge technology in the healthcare and life sciences fields in Japan.

Specifically, medical data, genomes, and other clinical data collected from medical institutions through Fujitsu's Healthy Living Platform, a medical data utilization platform, are processed into a format compliant with various regulations using the LLM of Fujitsu Kozuchi, an AI service, and provided to Paradigm Paradigm will also provide the data to Fujitsu Kozuchi's LLM, an AI service. Paradigm analyzes this data on its clinical trial platform and provides pharmaceutical companies with insights necessary for planning and conducting clinical trials. This enables pharmaceutical companies to significantly improve the efficiency of their clinical trial design work.

Medical institutions can also get early information on which trials their patients can participate in on Paradigm's clinical trial platform, making it easier to encourage patients to participate in clinical trials at the right time.
The two companies will deploy these solutions starting in September 2024, beginning with provision to core clinical research hospitals.

Overview diagram of the platform connecting medical institutions and pharmaceutical companies

2. offer "Patient-centric Clinical Trials," a new offering that improves operational efficiency through clinical trial-specific LLMs.
Hundreds of clinical trial-related documents that pharmaceutical companies need to create for new drug development are still manually created and managed. Fujitsu's clinical trial-specific LLM enables the automated creation of these vast amounts of documents in a regulatory-compliant manner.

Based on Fujitsu's strong track record in the clinical trial field and deep understanding of regulations, existing documents from pharmaceutical companies are automatically converted into a regulatory-compliant data structure. Furthermore, Fujitsu's clinical trial-specific LLM, which enables advanced tasks such as information retrieval, summarization, regulatory-compliant notation, and translation, which were previously performed by skilled professionals, automatically generates clinical trial-related documents from the converted data.

As a result of a demonstration test of this offering with a pharmaceutical company, 80% of each document could be created automatically by LLM. According to Fujitsu's estimate, the time required for document creation is expected to be reduced to 50%. Through this offering, Fujitsu will contribute to improving efficiency and shortening the time required for clinical trial planning at pharmaceutical companies.

About the future

Fujitsu will accelerate the digitalization of the clinical trial environment in Japan by providing comprehensive support for the entire process, including not only clinical trial planning work but also the execution phase of clinical trials, through further alliances with partners and the expansion of offerings. Through these efforts, Fujitsu aims to create the conditions for a large number of global clinical trials to be conducted in Japan and to eliminate drug loss.

Fujitsu will continue to promote its "Healthy Living" initiative, which seeks to improve people's wellbeing, and through the creation of new value by utilizing medical data, contribute to the realization of a society in which each individual can choose his or her own way of life.

Comments from Kent Thoelke, CEO, Paradigm Health, Inc.

Paradigm is very pleased to be working with Fujitsu to maximize its contribution to the efficiency of clinical trial operations in Japan. This partnership will modernize the clinical trial environment and help increase opportunities for patients in Japan to participate in clinical trials. By leveraging Fujitsu's industry-leading clinical trial platform and Fujitsu's broad range of healthcare solutions, we will increase the number of clinical trial options available to patients, reduce the time and cost of drug development, and eliminate drug loss in Japan. We are confident that this will enable Japan to become an integral part of the global clinical trial and drug development ecosystem, while ensuring that Japanese patients have equitable access to the best treatment options.

Trademarks.
Product names and other proper nouns mentioned herein are trademarks or registered trademarks of their respective companies.

[Annotation.
Note 1
Paradigm Health, Inc:
Headquarters: 175 S. 3rd Street, Suite 1000, Columbus, Ohio 43215, United States of America, CEO Kent Thoelke

Note 2
As of March 2023, there are 143 drugs that are in practical use overseas but not yet approved in Japan.
(Source: Ministry of Health, Labour and Welfare website) https://www.mhlw.go.jp/content/11121000/001206963.pdf

Related Link
Healthy Living's introduction page (Japanese only)https://activate.fujitsu/ja/uvance/healthy-living)
Patient-centric Clinical Trials introduction page (https://www.fujitsu.com/jp/solutions/uom/healthy-living/patient-centric-clinical-trials/)

[Press conference materials
August 26, 2024
Fujitsu Limitedhttps://pr.fujitsu.com/jp/news/2024/08/26b.pdf)

Fujitsu's Contribution to the SDGs

The Sustainable Development Goals (SDGs), adopted by the United Nations in 2015, are common goals that the entire world must achieve by 2030. Fujitsu's Purpose (raison d'être), "to make the world more sustainable by bringing trust to society through innovation," is a commitment to contribute to the SDGs.

The main SDGs to which this case aims to contribute

Fujitsu Limited|Corporate Profile

name of companyFujitsu Limited
EstablishmentJun. 1935
Location4-1-1 Kamikotanaka, Nakahara-ku, Kawasaki-shi, Kanagawa
representativeTakahito Tokita
uniform resouce locatorhttps://global.fujitsu/ja-jp
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。